JB Chemicals & Pharmaceuticals Limited

rs,

ironment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company

60%

ss multiple businesses 6 Brands among top 300 brands (IQVIA MAT Nov’22 data), contributing over 60% of domestic formulations revenues $2bn Market Cap on INR 152 billion (USD 1.85 bn)# Sales : IN

INR 152 billion

A MAT Nov’22 data), contributing over 60% of domestic formulations revenues $2bn Market Cap on INR 152 billion (USD 1.85 bn)# Sales : INR 24000 mn in FY 22 24% Growth in chronic therapies* in the domestic

INR 24000

0% of domestic formulations revenues $2bn Market Cap on INR 152 billion (USD 1.85 bn)# Sales : INR 24000 mn in FY 22 24% Growth in chronic therapies* in the domestic formulations business Top 5 Glob

24%

ions revenues $2bn Market Cap on INR 152 billion (USD 1.85 bn)# Sales : INR 24000 mn in FY 22 24% Growth in chronic therapies* in the domestic formulations business Top 5 Global manufacturer o

22%

entation 7 Multi-dosage formulation plants with key global regulatory approvals/compliances **22% ROCE with consistent cash flow generation generating good returns * CAGR over FY20-FY22 IQVIA M

54%

CE = EBIT/(Net Worth + Debt - Mutual Fund Investments) Increasing Share of the Domestic Revenue 54% 56% 46% 44% 52% 48% 46% 54% FY20 FY21 Domestic Formulations FY22 H1 FY23 International

56%

EBIT/(Net Worth + Debt - Mutual Fund Investments) Increasing Share of the Domestic Revenue 54% 56% 46% 44% 52% 48% 46% 54% FY20 FY21 Domestic Formulations FY22 H1 FY23 International Biz

46%

(Net Worth + Debt - Mutual Fund Investments) Increasing Share of the Domestic Revenue 54% 56% 46% 44% 52% 48% 46% 54% FY20 FY21 Domestic Formulations FY22 H1 FY23 International Biz 42%

44%

Worth + Debt - Mutual Fund Investments) Increasing Share of the Domestic Revenue 54% 56% 46% 44% 52% 48% 46% 54% FY20 FY21 Domestic Formulations FY22 H1 FY23 International Biz 42% 25%

52%

+ Debt - Mutual Fund Investments) Increasing Share of the Domestic Revenue 54% 56% 46% 44% 52% 48% 46% 54% FY20 FY21 Domestic Formulations FY22 H1 FY23 International Biz 42% 25% 22%

48%

bt - Mutual Fund Investments) Increasing Share of the Domestic Revenue 54% 56% 46% 44% 52% 48% 46% 54% FY20 FY21 Domestic Formulations FY22 H1 FY23 International Biz 42% 25% 22% 18%

Slide No.

1

Slide No.

25 JB publishes its First Sustainability Report – FY 2021-22 Reporting Framework: Report prepared in accordance with the GRI Standards: Core Option, and United Nations Sustainable Development Goals (UN SDGs) Reporting Period: This report covers the sustainability performance of the Company for the period 1st April 2021 till 31st March 2022 JB Pharma now among the few pharmaceutical companies in the country to release its sustainability report based on the Globally accepted GRI framework For detailed sustainability report, please visit: https://jbpharma.com/sustainability-report/ Jan 2023 JB Pharma 26 JB Pharma – Looking ahead Growth objectives supported by lean organization structure and strong governance framework Domestic business to consistently outperform market growth driven by  Big brands becoming bigger  Market share & prescription gains in acquired portfolio of probiotics, heart-failure, paediatric and Lipid-lowering segment  Life cycle management and new launches Continued